Shaanxi Micot Pharmaceutical Technology Co., Ltd.

陕西麦科奥特医药科技股份有限公司

02335.HK

Biotechnology company developing bi-/multi-specific peptide drugs for metabolic, cardiovascular and cerebrovascular diseases, with a Phase III core product for CKD-SHPT and three key clinical-stage candidates, all in-house developed, primarily in China.

Filings

The documents are on HKEXnews; we link to the originals.

Matters the filing discloses

From the company’s latest filing; open a kind of matter to see how other companies disclosed it.

• Supplier concentration
• Reliance on platforms, partners or licences
• Outsourced production (OEM / contract manufacturing)
• Business changes and acquisitions
• Losses and path to profitability
• Negative operating cash flow
• Cash burn and runway
• Preferred shares and fair-value liabilities
• Adverse change after the track record
• Non-recurring gains and losses
• Related-party transactions and balances
• Chapter 18A biotech